ClinicalTrials.gg
CompletedNCT05412030Updated Oct 9, 2026Results posted

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

A Phase 2 interventional study of AFX3772 and Prevnar 13 in Pneumonia, Bacterial, Pneumococcal Infections and Pneumonia, Pneumococcal, sponsored by GlaxoSmithKline. Completed at 52 sites in 2 countries. Open to participants aged 42 Days to 90 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Primary conditionPneumonia, PneumococcalRegistry: Pneumonia, BacterialReclassifiedWhy we changed it
Registry
Pneumonia, Bacterial — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pneumonia, Pneumococcal
Why
  1. The study's listed conditions name Pneumonia, Pneumococcal, a narrower term within Pneumonia, Bacterial.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Updated Oct 9, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
42 Days to 90 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Pneumonia, Pneumococcal with a site in United States — none open to participants now, none under way, none of them phase 3. Pneumonia, Pneumococcal · United States.

Enrollment
7th of 11
388 · median 431
Started
2022
with 2 others
Phase 2
2 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
GlaxoSmithKline

Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2022, is one of 2 in phase 2, and was the 8th registered.

Pneumonia, Pneumococcal

44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.

Browse Pneumonia, Pneumococcal studies →

Open to participants now

None of the 12 studies in Pneumonia, Pneumococcal with a site in United States is open now. The open studies under Pneumonia, Pneumococcal, anywhere →

Who these studies take

Of the 1 Pneumonia, Pneumococcal study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 42 Days to 90 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Pneumonia, Pneumococcal with a site in United States as a file.
02

Study summary

This is a Phase 2 clinical study evaluating AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of three different formulations of AFX3772 compared with Prevnar 13 (PCV13) and Prevnar 20 (PCV20).

Part 1 is the dose-escalation lead-in portion of the study, in which infants at each dose level are randomized 3:1 in sequential cohorts to receive increasing doses of AFX3772 or PCV13.

In Part 2, infants are randomized to receive either one of two dose levels of AFX3772 or PCV20.

On 31 October 2024, the study was placed on partial clinical hold by the U.S. Food and Drug Administration. The hold was not related to safety concerns in participants who had already received the study vaccines. As a result, enrollment was paused and no further doses of the investigational pneumococcal vaccine were administered. Participants who were already enrolled transitioned to the standard of care pneumococcal vaccine to complete their scheduled visits through post-dose 3 and subsequently completed study follow-up.

03

Conditions studied

  • Pneumonia, Bacterial
  • Pneumococcal Infections
  • Pneumonia, Pneumococcal

Keywords

  • Pneumonia, Pneumococcal
  • Infections
  • Streptococcal Infections
  • Pneumonia
04

In context

Pneumonia, Pneumococcal Reclassified

44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.

This study's enrollment of 388 is close to the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.

Browse Pneumonia, Pneumococcal studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Pneumonia, Pneumococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pneumonia, Bacterial. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
42 Days to 90 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has an LAR who understands study procedures, alternative treatments and risks involved in the study and who voluntarily agrees to participate by giving .
  2. Participant is a full-term (≥37 weeks gestation at birth) infant approximately 2 months of age (42 to 90 days, inclusive) at time of obtaining the informed consent.
  3. Participant is healthy based on the clinical judgment of the investigator following review of medical history and physical examination.

Exclusion criteria

Exclusion Criteria:

  1. Participant had prior administration of any pneumococcal vaccine.
  2. Participant has a known or suspected to AFX3772, PCV13, PCV20 or any components of the formulations used.
  3. Participant has a known or suspected immunodeficiency (including disease) or other conditions associated with that may require immunosuppressive drugs including but not limited to infection, or organ or bone marrow transplant.

    a. In addition, the participant's biological mother has known HIV infection or known to be surface antigen positive.

  4. Participant has any allergic condition or history (including anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to the first vaccination for primary immunization series.
  5. Participant has functional asplenia.
  6. Participant has medical history of epilepsy or febrile convulsion.
  7. Participant weighed \<2000 g at birth.
  8. Participant has known neurological or cognitive behavioral disorders including clinically significant developmental disorder and related disorders.
  9. Participant has any active malignancy or history of malignancy.
  10. Participant has a history of microbiologically proven invasive disease caused by S. pneumoniae.
  11. Participant has cochlear implant or cerebrospinal fluid leakage.
  12. Has received other licensed non- within the 14 days or a licensed live virus vaccine within the 30 days prior to receipt of study vaccine.
  13. Participant has received immunoglobulins. Note: This does not include monoclonal antibodies, such as palivizumab or nirsevimab.
  14. Participant has a bleeding diathesis or condition associated with prolonged bleeding that would contraindicate intramuscular injection.
  15. Participant has received systemic (equivalent of >2 mg/kg total daily dose of prednisone or >20 mg/day for persons weighing >10 kg) for a period of more than 14 days and has not completed the treatment for at least 30 days before study vaccine. Topical, ophthalmic, and inhaled steroids are allowed.
  16. Participant has febrile illness (rectal temperature ≥38.1°C [100.5°F] or axillary temperature ≥37.8°C [100.0°F]) in Part 1 and Part 2 prior to the effective date of protocol amendment 4. After protocol amendment 4 becomes effective, febrile illness is defined as rectal temperature ≥38.0°C [100.4°F] or axillary temperature ≥37.5°C (99.1°F) in Part 2. Upon resolution of symptoms, participant can be rescreened.
  17. Participant has received any therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
  18. Participant has any condition which, in the investigator's opinion, makes the participant unsuitable for study participation.
  19. LARs that are study personnel or their immediate dependents, family, or household members.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
388 participants (actual)

Study arms

  • Experimental
    Part 1: AFX3772 1 µg

    AFX3772 1 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV13 as standard of care.

    Biological: AFX3772 · Biological: Prevnar 13

  • Experimental
    Part 1: AFX3772 2 µg

    AFX3772 2 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV13 as standard of care.

    Biological: AFX3772 · Biological: Prevnar 13

  • Experimental
    Part 1: AFX3772 5 µg

    AFX3772 5 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV13 as standard of care.

    Biological: AFX3772 · Biological: Prevnar 13

  • Active comparator
    Part 1 Comparator: PCV13

    PCV13 was administered at 2, 4, and 6 months of age.

    Biological: Prevnar 13

  • Experimental
    Part 2: AFX3772 2 µg

    AFX3772 2 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV20 as standard of care.

    Biological: AFX3772 · Biological: Prevnar 20

  • Experimental
    Part 2: AFX3772 5 µg

    FX3772 5 µg was administered at 2, 4, and 6 months of age. Participants who did not receive a planned AFX3772 dose received PCV20 as standard of care.

    Biological: AFX3772 · Biological: Prevnar 20

  • Active comparator
    Part 2 Comparator: PCV20

    PCV20 was administered at 2, 4, and 6 months of age.

    Biological: Prevnar 20

Interventions

  • BiologicalAFX3772

    AFX3772 administered intramuscularly.

  • BiologicalPrevnar 13

    PCV13 administered intramuscularly.

    Also known as: PCV13

  • BiologicalPrevnar 20

    PCV 20 administered intramuscularly.

    Also known as: PCV20

07

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Any Solicited Injection Site Adverse Events (AEs) After First Dose

    The assessed solicited injection site events were pain/tenderness, redness/erythema and swelling/induration. Any = occurrence of the event regardless of the intensity grade.

    Time frame: Day 1 to Day 7 post dose 1

  2. Number of Participants Reporting Any Solicited Injection Site AEs After Second Dose

    Time frame: Day 1 to Day 7 post dose 2

  3. Number of Participants Reporting Any Solicited Injection Site AEs After Third Dose

    Time frame: Day 1 to Day 7 post dose 3

  4. Number of Participants Reporting Any Solicited Systemic Events After First Dose

    The assessed solicited systemic events are irritability, fever, appetite loss, increased sleep, and decrease in sleep. Any = occurrence of the event regardless of the intensity grade.

    Time frame: Day 1 to Day 7 post dose 1

  5. Number of Participants Reporting Any Solicited Systemic Events After Second Dose

    Time frame: Day 1 to Day 7 post dose 2

  6. Number of Participants Reporting Any Solicited Systemic Events After Third Dose

    Time frame: Day 1 to Day 7 post dose 3

  7. Number of Participants Reporting Any Unsolicited AEs

    An unsolicited AE was defined as any adverse event that was not actively solicited through the participant eDiary and was reported by the participant's legally authorized representative (LAR) or identified by site personnel. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the event regardless of the intensity grade.

    Time frame: Within 30 days post each dose (at 2, 4, and 6 months of age as part of primary vaccination series)

  8. Number of Participants Reporting Any Serious Adverse Events (SAEs)

    An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity. Medical or scientific judgment will be exercised by the investigator in deciding whether SAE reporting is appropriate in other situations such as significant medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.

    Time frame: Day 1 through 6 months post dose 3

Secondary outcomes

  1. Proportion of Participants With a Pneumococcal Serotype-specific Immunoglobulin G (IgG) Concentration of >= 0.35 μg/mL

    Immunogenicity data has not been presented since no participants completed the planned 3+1 vaccination regimen with the investigational vaccine and instead received standard-of-care pneumococcal vaccination.

    Time frame: 30 days post-dose 2 and 3

  2. Geometric Mean Concentration (GMC) for Serotype-specific IgG

    Immunogenicity data has not been presented since no participants completed the planned 3+1 vaccination regimen with the investigational vaccine and instead received standard-of-care pneumococcal vaccination.

    Time frame: 30 days post-dose 2 and 3

08

Results

Posted Oct 9, 2026

Participant flow

A total of 388 participants were enrolled in the study, including 130 in Part 1 and 258 in Part 2. Of these, 380 participants were randomized, and 376 participants received at least 1 dose of study vaccination.

Participant flow — Overall Study
MilestonePart 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20
Started31323130848686
Safety set30323029838686
Completed23242723557265
Not completed8847291421
Withdrew: Physician decision1000001
Withdrew: Withdrawal by subject430513910
Withdrew: Death0000100
Withdrew: Lost to follow-up01121214
Withdrew: Mis-randomization and not treated1000000
Withdrew: Protocol deviation affecting efficacy and/or safety0000111
Withdrew: Rescue medication0000222
Withdrew: Not, pre-specified2430013

Outcome measures

PrimaryNumber of Participants Reporting Any Solicited Injection Site Adverse Events (AEs) After First Dose

The assessed solicited injection site events were pain/tenderness, redness/erythema and swelling/induration. Any = occurrence of the event regardless of the intensity grade.

Time frame:
Day 1 to Day 7 post dose 1
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Injection Site Adverse Events (AEs) After First Dose
ParticipantsPart 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20
Tenderness16151117383634
Erythema95412251723
Swelling4267221618
PrimaryNumber of Participants Reporting Any Solicited Injection Site AEs After Second Dose
Time frame:
Day 1 to Day 7 post dose 2
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Injection Site AEs After Second Dose
ParticipantsPart 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20
Tenderness1815411181114
Erythema5344964
Swelling2234745
SecondaryProportion of Participants With a Pneumococcal Serotype-specific Immunoglobulin G (IgG) Concentration of >= 0.35 μg/mL

Immunogenicity data has not been presented since no participants completed the planned 3+1 vaccination regimen with the investigational vaccine and instead received standard-of-care pneumococcal vaccination.

Time frame:
30 days post-dose 2 and 3

Results for this outcome have not been posted.

SecondaryGeometric Mean Concentration (GMC) for Serotype-specific IgG

Immunogenicity data has not been presented since no participants completed the planned 3+1 vaccination regimen with the investigational vaccine and instead received standard-of-care pneumococcal vaccination.

Time frame:
30 days post-dose 2 and 3

Results for this outcome have not been posted.

PrimaryNumber of Participants Reporting Any Solicited Injection Site AEs After Third Dose
Time frame:
Day 1 to Day 7 post dose 3
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Injection Site AEs After Third Dose
ParticipantsPart 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20
Tenderness153091044
Erythema3103703
Swelling2003501
PrimaryNumber of Participants Reporting Any Solicited Systemic Events After First Dose

The assessed solicited systemic events are irritability, fever, appetite loss, increased sleep, and decrease in sleep. Any = occurrence of the event regardless of the intensity grade.

Time frame:
Day 1 to Day 7 post dose 1
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Systemic Events After First Dose
ParticipantsPart 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20
Irritability27212324545851
Appetite Loss96710241722
Increased Sleep17201620334235
Decrease in Sleep139711312619
Fever1131265
PrimaryNumber of Participants Reporting Any Solicited Systemic Events After Second Dose
Time frame:
Day 1 to Day 7 post dose 2
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Systemic Events After Second Dose
ParticipantsPart 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20
Irritability2521414251919
Appetite Loss96061058
Increased Sleep181439121414
Decrease in Sleep159210111111
Fever1101123
PrimaryNumber of Participants Reporting Any Solicited Systemic Events After Third Dose
Time frame:
Day 1 to Day 7 post dose 3
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Systemic Events After Third Dose
ParticipantsPart 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20
Irritability2090141648
Appetite Loss11306703
Increased Sleep105081147
Decrease in Sleep153061124
Fever2000222
PrimaryNumber of Participants Reporting Any Unsolicited AEs

An unsolicited AE was defined as any adverse event that was not actively solicited through the participant eDiary and was reported by the participant's legally authorized representative (LAR) or identified by site personnel. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the event regardless of the intensity grade.

Time frame:
Within 30 days post each dose (at 2, 4, and 6 months of age as part of primary vaccination series)
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Unsolicited AEs
ParticipantsPart 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20
Within 30 days, Post Dose 156108181912
Within 30 days, Post Dose 2128118212331
Within 30 days, Post Dose 37467142522
PrimaryNumber of Participants Reporting Any Serious Adverse Events (SAEs)

An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity. Medical or scientific judgment will be exercised by the investigator in deciding whether SAE reporting is appropriate in other situations such as significant medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.

Time frame:
Day 1 through 6 months post dose 3
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Serious Adverse Events (SAEs)
ParticipantsPart 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20
Number of Participants Reporting Any Serious Adverse Events (SAEs)3122761

Adverse events

Collected over Solicited AEs: Day 1 - Day 7 post each vaccination, Unsolicited AEs: Day 1 - Day 30 post each vaccination. All-Cause mortality, SAEs: Day 1 through 6 months post dose 3. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: AFX3772 1 µg0/30 (0%)3/30 (10%)30/30 (100%)
Part 1: AFX3772 2 µg0/32 (0%)1/32 (3.1%)30/32 (93.8%)
Part 1: AFX3772 5 µg0/30 (0%)2/30 (6.7%)28/30 (93.3%)
Part 1 Comparator: PCV130/29 (0%)2/29 (6.9%)29/29 (100%)
Part 2: AFX3772 2 µg1/83 (1.2%)7/83 (8.4%)74/83 (89.2%)
Part 2: AFX3772 5 µg0/86 (0%)6/86 (7%)77/86 (89.5%)
Part 2 Comparator: PCV200/86 (0%)1/86 (1.2%)78/86 (90.7%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPart 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20
BronchiolitisInfections and infestations1/300/320/301/292/832/860/86
StereotypyPsychiatric disorders0/300/320/301/290/830/860/86
Respiratory syncytial virus bronchiolitisInfections and infestations1/301/320/300/292/832/861/86
Escherichia urinary tract infectionInfections and infestations0/300/321/300/290/830/860/86
Gastroenteritis viralInfections and infestations1/300/320/300/290/830/860/86
HaematemesisGastrointestinal disorders1/300/320/300/290/830/860/86
Failure to thriveMetabolism and nutrition disorders0/300/321/300/290/830/860/86
CellulitisInfections and infestations0/300/320/300/291/831/860/86
InfluenzaInfections and infestations0/300/320/300/291/830/860/86
Head injuryInjury, poisoning and procedural complications0/300/320/300/291/830/860/86
Most frequent other events
Showing 10 of 137
Most frequent other events
EventPart 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20
IrritabilityGeneral disorders30/3027/3224/3027/2959/8370/8664/86
Sleep deficitNervous system disorders24/3018/3213/3018/2943/8345/8638/86
TendernessGeneral disorders23/3023/3219/3022/2948/8353/8649/86
Increased need for sleepNervous system disorders22/3024/3221/3022/2942/8348/8648/86
Decreased appetiteGeneral disorders17/3011/3211/3013/2933/8330/8633/86
Injection site erythemaGeneral disorders13/307/3210/3015/2934/8328/8638/86
Injection site swellingGeneral disorders5/304/329/3010/2931/8327/8628/86
InsomniaPsychiatric disorders6/301/322/300/290/830/860/86
PyrexiaGeneral disorders1/301/321/301/299/8316/8610/86
IrritabilityPsychiatric disorders4/301/324/302/290/831/860/86

Baseline characteristics

Analysis was performed on the Safety Analysis Set (SAF) which includes all the participants who were randomized and received at least 1 study vaccination with either AFX3772 or PCV.

Age, Continuous
Age, Continuous(Days)Part 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20Total
Part 166.6 ± 6.8364.6 ± 5.8965.9 ± 13.9865.7 ± 8.45———65.7 ± 9.20
Part 2————65.7 ± 9.5964.7 ± 8.6065.2 ± 8.4065.2 ± 8.85
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Part 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20Total
Male16121514434046186
Female14201515404640190
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: AFX3772 1 µgPart 1: AFX3772 2 µgPart 1: AFX3772 5 µgPart 1 Comparator: PCV13Part 2: AFX3772 2 µgPart 2: AFX3772 5 µgPart 2 Comparator: PCV20Total
American Indian or Alaska Native001062110
Asian12010105
Native Hawaiian or Other Pacific Islander10000001
Black or African American11201192145
White or Caucasian23272325536452267
Mutiple224386530
Other200054718
09

Study locations

52 sites
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    Gardena, California 90247, United States
  • GSK Investigational Site
    Los Angeles, California 90057, United States
  • GSK Investigational Site
    Madera, California 93637, United States
  • GSK Investigational Site
    Ontario, California 91762, United States
  • GSK Investigational Site
    Miami, Florida 33184, United States
  • GSK Investigational Site
    Pensacola, Florida 32503, United States
  • GSK Investigational Site
    Saint Augustine, Florida 32086-5774, United States
  • GSK Investigational Site
    Tampa, Florida 33613, United States
  • GSK Investigational Site
    Tampa, Florida 33617, United States
  • GSK Investigational Site
    Nampa, Idaho 83702, United States
  • GSK Investigational Site
    Bardstown, Kentucky 40004, United States
  • GSK Investigational Site
    Lexington, Kentucky 40517, United States
  • GSK Investigational Site
    Louisville, Kentucky 40291, United States
  • GSK Investigational Site
    Covington, Louisiana 70433, United States
  • GSK Investigational Site
    Haughton, Louisiana 71037, United States
  • GSK Investigational Site
    Lafayette, Louisiana 70508, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70119-7100, United States
  • GSK Investigational Site
    Mankato, Minnesota 56001, United States
  • GSK Investigational Site
    Missoula, Montana 59804, United States
  • GSK Investigational Site
    Hastings, Nebraska 68901, United States
  • GSK Investigational Site
    Norfolk, Nebraska 68701-7701, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45245, United States
  • GSK Investigational Site
    Cleveland, Ohio 44121, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74104, United States
  • GSK Investigational Site
    Cranberry Township, Pennsylvania 16006, United States
  • GSK Investigational Site
    Jefferson Hills, Pennsylvania 15025, United States
  • GSK Investigational Site
    N. Huntingdon, Pennsylvania 15642, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213-3205, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15217-1212, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15234, United States
  • GSK Investigational Site
    Charleston, South Carolina 29407-4726, United States
  • GSK Investigational Site
    Greenville, South Carolina 29607, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29301, United States
  • GSK Investigational Site
    Brownsville, Texas 78520, United States
  • GSK Investigational Site
    Dallas, Texas 75230-2501, United States
  • GSK Investigational Site
    Dickinson, Texas 77539, United States
  • GSK Investigational Site
    Houston, Texas 77065-5470, United States
  • GSK Investigational Site
    Houston, Texas 77071, United States
  • GSK Investigational Site
    Houston, Texas 77077, United States
  • GSK Investigational Site
    Houston, Texas 77087-1122, United States
  • GSK Investigational Site
    McAllen, Texas 78504, United States
  • GSK Investigational Site
    Richmond, Texas 77469, United States
  • GSK Investigational Site
    Layton, Utah 84041, United States
  • GSK Investigational Site
    Roy, Utah 84067, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84107, United States
  • GSK Investigational Site
    South Jordan, Utah 84095-3211, United States
  • GSK Investigational Site
    Syracuse, Utah 84075-9645, United States
  • GSK Investigational Site
    Bayamón, 960, Puerto Rico
  • GSK Investigational Site
    Caguas, 00725, Puerto Rico
  • GSK Investigational Site
    Ponce, 00716-0377, Puerto Rico
  • GSK Investigational Site
    San Juan, 00935-6528, Puerto Rico
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Sep 2025, 39 months.

Results were first posted in Oct 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2022
First posted
Jun 9, 2022
StartActual
Jun 16, 2022
Primary completionActual
Sep 18, 2025
CompletionActual
Sep 18, 2025
Results first posted
Oct 9, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 9, 2026
Sites
7 sites added, 1 site removed
Show 7 added (7 United States)
  • GSK Investigational Site · Gardena, United States
  • GSK Investigational Site · Madera, United States
  • GSK Investigational Site · Ontario, United States
  • GSK Investigational Site · Tampa, United States
  • GSK Investigational Site · Norfolk, United States
  • GSK Investigational Site · Cleveland, United States
  • GSK Investigational Site · Houston, United States
Show 1 removed
  • GSK Investigational Site · Norfolk, United States
Oct 9, 2026
Eligibility
1 inclusion criterion edited, 2 added; 7 exclusion criteria edited, 13 added, 1 removed
What changed in the criteria
Inclusion criteria
  • AddedParticipant has an LAR who understands study procedures, alternative treatments and risks involved in the study and who voluntarily agrees to participate by giving informed consent.
  • EditedIsParticipant is a full-term (≥37 weeks gestation at birth) infant approximately 2 months of age (42 to 90 days, inclusive) at time of obtaining the informed consent.
  • AddedParticipant is healthy based on the clinical judgment of the investigator following review of medical history and physical examination.
Exclusion criteria
  • EditedHadParticipant had prior administration of any pneumococcal vaccine.
  • EditedHasParticipant has a known or suspected hypersensitivity to AFX3772, PCV13, PCV20 or any components of the formulations used.
  • AddedParticipant has a known or suspected immunodeficiency (including autoimmune disease) or other conditions associated with immunosuppression that may require immunosuppressive drugs including but not limited to HIV infection, malignancy or organ or bone marrow transplant.
  • EditedHas a known or suspected immunodeficiency or other conditions associated with immunosuppression that may require immunosuppressive drugs. In addition, the participant's biological mother has known HIV infection or known to be hepatitis B surface antigen positive.
  • EditedHasParticipant has any clinically significant allergic condition or history (including anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to the first vaccination for primary immunization series.
  • AddedParticipant has functional asplenia.
  • AddedParticipant has medical history of epilepsy or febrile convulsion.
  • AddedParticipant weighed <2000 g at birth.
  • AddedParticipant has known neurological or cognitive behavioral disorders including clinically significant developmental disorder and related disorders.
  • AddedParticipant has any active malignancy or history of malignancy.
  • EditedHasParticipant has a history of microbiologically proven invasive disease caused by S. pneumoniae.
  • RemovedHas received immunoglobulins.
  • AddedParticipant has cochlear implant or cerebrospinal fluid leakage.
  • AddedHas received other licensed non-live vaccines within the 14 days or a licensed live virus vaccine within the 30 days prior to receipt of study vaccine.
  • AddedParticipant has received immunoglobulins. Note: This does not include monoclonal antibodies, such as palivizumab or nirsevimab.
  • EditedHasParticipant has a bleeding diathesis or condition associated with prolonged bleeding that would contraindicate intramuscular injection.
  • EditedHasParticipant has received systemic corticosteroids (equivalent of >2 mg/kg total daily dose of prednisone or >20 mg/day for persons weighing >10 kg) for a period of more than 14 days and has not completed the treatment for at least 30 days before study vaccine. Topical, ophthalmic, and inhaled steroids are allowed.
  • AddedParticipant has febrile illness (rectal temperature ≥38.1°C [100.5°F] or axillary temperature ≥37.8°C [100.0°F]) in Part 1 and Part 2 prior to the effective date of protocol amendment 4. After protocol amendment 4 becomes effective, febrile illness is defined as rectal temperature ≥38.0°C [100.4°F] or axillary temperature ≥37.5°C (99.1°F) in Part 2. Upon resolution of symptoms, participant can be rescreened.
  • AddedParticipant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
  • AddedParticipant has any condition which, in the investigator's opinion, makes the participant unsuitable for study participation.
  • AddedLARs that are study personnel or their immediate dependents, family, or household members.
Oct 9, 2026
Interventions
Arm changed Part 1 Group 1→Part 1: AFX3772 1 µg; Part 1 Group 2→Part 1: AFX3772 2 µg; Part 2 Group 5→Part 2: AFX3772 5 µg. Arms added: Part 1: AFX3772 5 µg·Part 1 Comparator: PCV13·Part 2: AFX3772 2 µg·Part 2 Comparator: PCV20; arms removed: Part 1 Group 3·Part 1 Group 4·Part 2 Group 6·Part 2 Group 7
Oct 9, 2026
Primary outcomes
4 edited, 4 added
What changed in the outcomes
  • EditedPercentageNumber of participants with solicited injection site eventsParticipants Reporting Any Solicited Injection Site Adverse Events (AEs) After First DoseTime frame: Day 1 through Day 7 post-vaccination → Day 1 to Day 7 post dose 1
  • EditedPercentageNumber of participants with solicited systemic eventsParticipants Reporting Any Solicited Systemic Events After First DoseTime frame: Day 1 through Day 7 post-vaccination → Day 1 to Day 7 post dose 1
  • EditedPercentageNumber of participants withParticipants Reporting Any Unsolicited AEsTime frame: Day 1 through Day 30 → Within 30 days post each dose (at 2, 4, and 6 months of age as part of primary vaccination series)
  • EditedPercentageNumber of participants with serious adverse eventsParticipants Reporting Any Serious Adverse Events (SAEs)Time frame: Day 1 through 6 months post dose three → Day 1 through 6 months post dose 3
  • AddedNumber of Participants Reporting Any Solicited Injection Site AEs After Second DoseTime frame: Day 1 to Day 7 post dose 2
  • AddedNumber of Participants Reporting Any Solicited Injection Site AEs After Third DoseTime frame: Day 1 to Day 7 post dose 3
  • AddedNumber of Participants Reporting Any Solicited Systemic Events After Second DoseTime frame: Day 1 to Day 7 post dose 2
  • AddedNumber of Participants Reporting Any Solicited Systemic Events After Third DoseTime frame: Day 1 to Day 7 post dose 3
Oct 9, 2026
Documents
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedPercentageProportion of participants withParticipants With a pneumococcal serotypePneumococcal Serotype-specific Immunoglobulin G (IgG) concentrationConcentration of greater than or equal to (>=) 0.35 μg/mL or corresponding thresholdTime frame: 30 days post-dose two, 30 days post-dose three → 30 days post-dose 2 and 3
  • EditedGeometric mean concentrationMean Concentration (GMC) for serotypeSerotype-specific IgGTime frame: 30 days post-dose two, 30 days post-dose three → 30 days post-dose 2 and 3
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Results posted
    7 sites added, 1 site removed
    Show 7 added (7 United States)
    • GSK Investigational Site · Gardena, United States
    • GSK Investigational Site · Madera, United States
    • GSK Investigational Site · Ontario, United States
    • GSK Investigational Site · Tampa, United States
    • GSK Investigational Site · Norfolk, United States
    • GSK Investigational Site · Cleveland, United States
    • GSK Investigational Site · Houston, United States
    Show 1 removed
    • GSK Investigational Site · Norfolk, United States
    Eligibility 1 inclusion criterion edited, 2 added; 7 exclusion criteria edited, 13 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • AddedParticipant has an LAR who understands study procedures, alternative treatments and risks involved in the study and who voluntarily agrees to participate by giving informed consent.
    • EditedIsParticipant is a full-term (≥37 weeks gestation at birth) infant approximately 2 months of age (42 to 90 days, inclusive) at time of obtaining the informed consent.
    • AddedParticipant is healthy based on the clinical judgment of the investigator following review of medical history and physical examination.
    Exclusion criteria
    • EditedHadParticipant had prior administration of any pneumococcal vaccine.
    • EditedHasParticipant has a known or suspected hypersensitivity to AFX3772, PCV13, PCV20 or any components of the formulations used.
    • AddedParticipant has a known or suspected immunodeficiency (including autoimmune disease) or other conditions associated with immunosuppression that may require immunosuppressive drugs including but not limited to HIV infection, malignancy or organ or bone marrow transplant.
    • EditedHas a known or suspected immunodeficiency or other conditions associated with immunosuppression that may require immunosuppressive drugs. In addition, the participant's biological mother has known HIV infection or known to be hepatitis B surface antigen positive.
    • EditedHasParticipant has any clinically significant allergic condition or history (including anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to the first vaccination for primary immunization series.
    • AddedParticipant has functional asplenia.
    • AddedParticipant has medical history of epilepsy or febrile convulsion.
    • AddedParticipant weighed <2000 g at birth.
    • AddedParticipant has known neurological or cognitive behavioral disorders including clinically significant developmental disorder and related disorders.
    • AddedParticipant has any active malignancy or history of malignancy.
    • EditedHasParticipant has a history of microbiologically proven invasive disease caused by S. pneumoniae.
    • RemovedHas received immunoglobulins.
    • AddedParticipant has cochlear implant or cerebrospinal fluid leakage.
    • AddedHas received other licensed non-live vaccines within the 14 days or a licensed live virus vaccine within the 30 days prior to receipt of study vaccine.
    • AddedParticipant has received immunoglobulins. Note: This does not include monoclonal antibodies, such as palivizumab or nirsevimab.
    • EditedHasParticipant has a bleeding diathesis or condition associated with prolonged bleeding that would contraindicate intramuscular injection.
    • EditedHasParticipant has received systemic corticosteroids (equivalent of >2 mg/kg total daily dose of prednisone or >20 mg/day for persons weighing >10 kg) for a period of more than 14 days and has not completed the treatment for at least 30 days before study vaccine. Topical, ophthalmic, and inhaled steroids are allowed.
    • AddedParticipant has febrile illness (rectal temperature ≥38.1°C [100.5°F] or axillary temperature ≥37.8°C [100.0°F]) in Part 1 and Part 2 prior to the effective date of protocol amendment 4. After protocol amendment 4 becomes effective, febrile illness is defined as rectal temperature ≥38.0°C [100.4°F] or axillary temperature ≥37.5°C (99.1°F) in Part 2. Upon resolution of symptoms, participant can be rescreened.
    • AddedParticipant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
    • AddedParticipant has any condition which, in the investigator's opinion, makes the participant unsuitable for study participation.
    • AddedLARs that are study personnel or their immediate dependents, family, or household members.
    Primary outcomes 4 edited, 4 added
    What changed in the outcomes
    • EditedPercentageNumber of participants with solicited injection site eventsParticipants Reporting Any Solicited Injection Site Adverse Events (AEs) After First DoseTime frame: Day 1 through Day 7 post-vaccination → Day 1 to Day 7 post dose 1
    • EditedPercentageNumber of participants with solicited systemic eventsParticipants Reporting Any Solicited Systemic Events After First DoseTime frame: Day 1 through Day 7 post-vaccination → Day 1 to Day 7 post dose 1
    • EditedPercentageNumber of participants withParticipants Reporting Any Unsolicited AEsTime frame: Day 1 through Day 30 → Within 30 days post each dose (at 2, 4, and 6 months of age as part of primary vaccination series)
    • EditedPercentageNumber of participants with serious adverse eventsParticipants Reporting Any Serious Adverse Events (SAEs)Time frame: Day 1 through 6 months post dose three → Day 1 through 6 months post dose 3
    • AddedNumber of Participants Reporting Any Solicited Injection Site AEs After Second DoseTime frame: Day 1 to Day 7 post dose 2
    • AddedNumber of Participants Reporting Any Solicited Injection Site AEs After Third DoseTime frame: Day 1 to Day 7 post dose 3
    • AddedNumber of Participants Reporting Any Solicited Systemic Events After Second DoseTime frame: Day 1 to Day 7 post dose 2
    • AddedNumber of Participants Reporting Any Solicited Systemic Events After Third DoseTime frame: Day 1 to Day 7 post dose 3
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedPercentageProportion of participants withParticipants With a pneumococcal serotypePneumococcal Serotype-specific Immunoglobulin G (IgG) concentrationConcentration of greater than or equal to (>=) 0.35 μg/mL or corresponding thresholdTime frame: 30 days post-dose two, 30 days post-dose three → 30 days post-dose 2 and 3
    • EditedGeometric mean concentrationMean Concentration (GMC) for serotypeSerotype-specific IgGTime frame: 30 days post-dose two, 30 days post-dose three → 30 days post-dose 2 and 3
    Interventions Arm changed Part 1 Group 1→Part 1: AFX3772 1 µg; Part 1 Group 2→Part 1: AFX3772 2 µg; Part 2 Group 5→Part 2: AFX3772 5 µg. Arms added: Part 1: AFX3772 5 µg·Part 1 Comparator: PCV13·Part 2: AFX3772 2 µg·Part 2 Comparator: PCV20; arms removed: Part 1 Group 3·Part 1 Group 4·Part 2 Group 6·Part 2 Group 7
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05412030
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 9, 2022
Start date
Jun 16, 2022
Primary completion
Sep 18, 2025
Completion
Sep 18, 2025
Results posted
Oct 9, 2026
Last update
Oct 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 13-valent pneumococcal vaccine · Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion